Dr. Richard A. Nash, MD

Dr. Nash practices at HealthONE Clinic Services - Oncology Hematology in Denver, Colorado.

Dr. Nash's NPI, 1194815050, was assigned on October 13, 2006. Dr. Nash graduated from University of Laval Faculty of Medicine in 1977. Dr. Nash holds Colorado license 49931.

Dr. Nash's primary practice is HealthONE Clinic Services - Oncology Hematology, at 1721 E 19th Ave, Denver, CO 80218 in Denver County. The practice phone is (720) 754-4800.

Dr. Nash's primary practice is HealthONE Clinic Services - Oncology Hematology in Denver, Colorado. Dr. Nash is also affiliated with HCA HealthONE Presbyterian St. Luke's. The medical group on file is HCA HealthONE Physicians. Dmand AI also links Dr. Nash to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nash practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Nash's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Nash is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Nash's licenses on file in 2 states: Colorado and Washington.

Dmand AI lists lymphoma and multiple myeloma among the conditions Dr. Nash treats.

CMS data shows 16,653 Medicare services from Dr. Nash across 19 procedure codes in 2024, for 231 Medicare patients. Medicare paid $518,416 for them. Every service was in an office.

CMS counts 231 Medicare patients who saw Dr. Nash in 2024. The largest group is 65 to 74, with 120 patients. 65% of them have high cholesterol, and 63% have high blood pressure. 12% are also on Medicaid. Their average risk score is 3.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nash's median patient age at 65, with 44% women.

In 2024, Dr. Nash wrote 597 Medicare Part D claims for 46 patients. 81% of them were for generic drugs. CMS names the drug for 358 of them, across 17 drugs with 11 or more claims each, at $950,332 in total drug cost. In 2023, CMS named 265 claims across 13 drugs.

Dr. Nash accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nash as offering telehealth.

Dmand AI links 181 papers to Dr. Nash, published from 2003 to 2024. 2017 was the busiest year, with 5. The most frequent topics are Hematopoietic Stem Cell Transplantation, Transplantation, Homologous and Bone Marrow Transplantation. Dr. Nash has published most often in Blood. Dr. Nash's most frequent co-authors are Claudio Anasetti, MD, Daniel E. Furst, MD and Maureen D. Mayes, MD.

Dmand AI links Dr. Nash to 16 clinical trials, 11 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Scleroderma, Systemic, Graft vs Host Disease and Sclerosis. Fred Hutchinson Cancer Center sponsors the most, 7.

CMS Open Payments shows 70 general payments to Dr. Nash from 24 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 89% of the total. Abbvie Inc. paid the most, $329.

Dr. Nash graduated from University of Laval Faculty of Medicine in 1977.

Dr. Nash is in network with 17 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.